Sequential Changes Of Serum P53 Antibodies And Clinical Significance In Esophageal Carcinoma Radiotherapy

Objective To explore the relationship between serum p53 antibodies (p53-Abs) and clinicopathological characteristics and therapeutic effect in patients with esophageal carcinoma, and to investigate sequential changing regularity of serum p53-Abs after radiotherapy.Methods The serum p53 antibody (p53-Ab) level was detected in 46 patients with esophageal carcinoma, and in 30 healthy adults as control by enzyme linked immunosorbent assay (ELISA). The blood samples were collected on the day before radiotherapy and on the administration of an irradiation dose of 20Gy/10f/12d, 40Gy/20f/24d, 60Gy/30f/36 after radiotherapy.Results The level and positive rate of serum p53-Abs in patients with esophageal carcinoma were significantly higher than those in normal individuals (P<0.05). Serum anti-P53 antibodies were positive in 18 of 46 patients with esophageal carcinoma (39. 1%). The positive rate of serum p53-Abs in esophageal carcinoma was related with histological grade, disease stage and lymph node metastasis (P<0.05), but it was no significantly related with sex, age, the size and site of tumor (P >0.05). The level and positive rate of serum p53-Abs had significant differences between before radiotherapy, after administration of an irradiation dose of 40Gy/20f/24d and after administration of an irradiation dose of 60Gy/30f/36d (P<0. 05 or P<0.01). The positive rate of serum p53-Abs in effective patients with esophageal carcinoma was significantly lower than those in ineffective individuals after radiotherapy (P< 0.05).Conclusion Detection of serum p53-Abs is helpful to diagnosis of esophageal carcinoma. Monitoring of sequential change of before and after radiotherapy serum p53-Abs in patients with esophageal carcinoma is helpful to evaluate response to treatment, to judge prognosis of patients with esophageal carcinoma.